Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose S-033188 vs placebo or oseltamivir in high-risk influenza patients
2016-002688-32Phase 3Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of baloxavir marboxil in influenza (3 arms), sponsored by Shionogi & Co., Ltd. Primary endpoints: Time to improvement of influenza symptoms (S-033188 vs placebo) and Time to improvement of influenza symptoms (S-033188 vs oseltamivir). Started May 2017; status: completed.
02
Drugs
baloxavir marboxil
03
Conditions
influenza
Beyond the preview
Go deeper on 2016-002688-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002688-32.